Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors

REFERENCES

• Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab. 2003; 5(1)13–26
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992; 327(10)685–691, Erratum: N Engl J Med. 1992; 327(24):1768.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993; 329(20)1456–1462, Erratum: N Engl J Med. 1993; 330(2):152.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354(9176)359–364
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999; 100(23)2312–2318
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709–717
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321(7274)1440–1444
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355(9215)1582–1587
   PubMed Web of Science ®Google Scholar
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000; 355(9200)253–259, Erratum: Lancet. 2000; 356(9232):860.
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870–878
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861–869
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851–860
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349(20)1893–1906
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet. 2003; 362(9386)759–766
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, , for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309–1321
   PubMed Web of Science ®Google Scholar
• Manolio TA, Cutler JA, Furberg C, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155(8)829–837
   PubMedGoogle Scholar
• Carter BL, Malone DC, Ellis SL, et al. Antihypertensive drug utilization in hypertensive veterans with complex medication profiles. J Clin Hypertens (Greenwich). 2000; 2(3)172–180
   PubMedGoogle Scholar
• Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by U.S. office-based physicians. Hypertension. 2000; 36(4)600–603
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Bjornson DC. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes. Ann Pharmacother. 2000; 34(9)1002–1006
   PubMed Web of Science ®Google Scholar
• Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004; 141(2)95–101
   PubMed Web of Science ®Google Scholar
• Szczech LA, Lazar IL. Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int Suppl. 2004; 90: S3–S7
   PubMedGoogle Scholar
• Jones CA, Krolewski AS, Rogus J, et al. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause?. Kidney Int. 2005; 67(5)1684–1691
   PubMed Web of Science ®Google Scholar
• Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006; 69: 913–919
   PubMed Web of Science ®Google Scholar
• Silas JH, Klenka Z, Solomon SA. Captopril induced reversible renal failure: A marker of renal artery stenosis affecting a solitary kidney. Br Med J (Clin Res Ed). 1983; 286(6379)1702–1703
   PubMedGoogle Scholar
• Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed). 1984; 288(6420)844–845
   PubMedGoogle Scholar
• Jackson B, McGrath BP, Matthews PG, et al. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension. 1986; 8: 650–654
   PubMed Web of Science ®Google Scholar
• Kalra PA, Mamtora H, Holmes AM, et al. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med. 1990; 7(282)1013–1018
   Google Scholar
• Devoy MAB, Tomson CR, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med. 1992; 232(6)493–498
   PubMed Web of Science ®Google Scholar
• Thomas MC. Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Aust. 2000; 172(4)184–185
   PubMed Web of Science ®Google Scholar
• Boyd IW, Mathew TH, Thomas MC. Cox-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust. 2000; 173: 274
   PubMed Web of Science ®Google Scholar
• Descombes E, Fellay G. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency. Ren Fail. 2000; 22(6)815–821
   PubMed Web of Science ®Google Scholar
• Vachharajani TJ, Dacie JE, Yaqoob MM, et al. Detection of occult renovascular disease in unexplained chronic kidney disease. Int Urol Nephrol. 2005; 37(4)793–796
   PubMedGoogle Scholar
• Schalekamp MADH, Wenting GJ. Angiotensin converting enzyme inhibition in renovascular hypertension: Failure of the stenotic kidney. Lancet. 1984; 1(8374)464
   PubMed Web of Science ®Google Scholar
• Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Eng J Med. 1983; 308(7)373–376
   PubMed Web of Science ®Google Scholar
• Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Split renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed). 1984; 288(6421)886–890
   PubMedGoogle Scholar
• Jackson B, Matthews PG, McGrath BP, et al. Angiotensin converting enzyme inhibition in renovascular hypertension: Frequency of reversible renal failure. Lancet. 1984; 1(8370)225–226
   PubMed Web of Science ®Google Scholar
• Hollenberg NK. Angiotenisn-converting enzyme inhibition: Renal aspects. J Cardiovasc Pharmacol. 1985; 7: S40–S44
   Web of Science ®Google Scholar
• Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int. 1995; 47(6)1726–1731
   Google Scholar
• Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Ann Intern Med. 1997; 51(3)793–797
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6)461–470
   PubMed Web of Science ®Google Scholar
• Onuigbo MAC, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirty-month Mayo Health system Clinic experience. Med Sci Monit. 2005; 11(10)CR462–CR469
   PubMed Web of Science ®Google Scholar
• Onuigbo MAC, Onuigbo NTC. Late-onset renal failure from RAAS blockade. Kidney Int. 2006; 70: 1378–1379
   PubMed Web of Science ®Google Scholar
• Raine AE. Angiotensin-converting enzyme inhibition and renovascular disease. Q J Med. 1990; 77(282)997–999
   PubMedGoogle Scholar
• Ballermann BJ, Onuigbo MAC. Angiotensins. Handbook of Physiology. Section 7, The Endocrine System, Vol III. Endocrine Regulation of water and Electrolyte Balance., JCS Frsy. Oxford University Press, New York 2000; 104–155
   Google Scholar
• Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med. 2000; 160(5)685–693
   PubMed Web of Science ®Google Scholar